Try our Advanced Search for more refined results

June 17, 2021

Exelixis, Inc. v. Teva Pharmaceuticals Development, Inc., et al

View recent docket activity

Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.

Coverage

  1. July 25, 2023

    Teva Exits Cancer Drug IP Row With 2031 Generic License

    The maker of blockbuster cancer treatment Cabometyx has dropped patent litigation against Teva Pharmaceuticals over a planned generic, instead striking a licensing deal that permits an off-brand version of the drug to be released in 2031.

Parties

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Direct access to case information and documents.
  • All significant new filings across U.S. federal district courts, updated hourly on business days.
  • Full-text searches on all patent complaints in federal courts.
  • No-fee downloads of the complaints and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

View the parties now

Already a subscriber? Click here to login